CVS Health (NYSE:CVS) had its price objective lifted by Leerink Swann from $82.00 to $90.00 in a research report report published on Monday, Marketbeat Ratings reports. Leerink Swann currently has an outperform rating on the pharmacy operator’s stock. Leerink Swann also issued estimates for CVS Health’s Q4 2017 earnings at $1.90 EPS, FY2017 earnings at $5.90 EPS, Q1 2018 earnings at $1.31 EPS, Q2 2018 earnings at $1.63 EPS and Q3 2018 earnings at $1.91 EPS.
Several other research analysts have also weighed in on CVS. Needham & Company LLC reissued a hold rating on shares of CVS Health in a research report on Sunday, September 10th. Jefferies Group lifted their price objective on CVS Health from $82.00 to $86.00 and gave the stock a hold rating in a research report on Friday, September 15th. Royal Bank of Canada initiated coverage on CVS Health in a research report on Tuesday, September 19th. They issued an outperform rating and a $95.00 price objective for the company. Oppenheimer reissued a buy rating and issued a $95.00 price objective on shares of CVS Health in a research report on Monday, October 9th. Finally, SunTrust Banks set a $85.00 price objective on CVS Health and gave the stock a buy rating in a research report on Thursday, October 12th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the company’s stock. CVS Health has a consensus rating of Buy and a consensus target price of $86.66.
Shares of CVS Health (CVS) traded down $0.22 during trading hours on Monday, reaching $78.80. The company had a trading volume of 4,408,353 shares, compared to its average volume of 9,296,125. The company has a market cap of $79,970.00, a price-to-earnings ratio of 16.28, a P/E/G ratio of 1.38 and a beta of 0.90. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.55 and a current ratio of 1.05. CVS Health has a twelve month low of $66.45 and a twelve month high of $84.72.
CVS Health (NYSE:CVS) last announced its earnings results on Monday, November 6th. The pharmacy operator reported $1.50 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.49 by $0.01. CVS Health had a return on equity of 16.96% and a net margin of 2.77%. The business had revenue of $46.18 billion during the quarter, compared to analyst estimates of $46.17 billion. During the same period last year, the company earned $1.64 EPS. CVS Health’s revenue for the quarter was up 3.5% compared to the same quarter last year. equities analysts anticipate that CVS Health will post 5.9 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Friday, February 2nd. Investors of record on Wednesday, January 24th will be given a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 2.54%. The ex-dividend date is Tuesday, January 23rd. CVS Health’s payout ratio is 41.32%.
In related news, EVP Lisa Bisaccia sold 29,445 shares of the business’s stock in a transaction dated Thursday, December 21st. The stock was sold at an average price of $75.00, for a total value of $2,208,375.00. Following the completion of the sale, the executive vice president now directly owns 15,556 shares of the company’s stock, valued at approximately $1,166,700. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.61% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in the business. Jackson Grant Investment Advisers Inc. boosted its stake in CVS Health by 0.6% during the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 2,881 shares of the pharmacy operator’s stock valued at $232,000 after purchasing an additional 18 shares during the last quarter. Elefante Mark B boosted its stake in CVS Health by 0.7% during the 2nd quarter. Elefante Mark B now owns 6,400 shares of the pharmacy operator’s stock valued at $515,000 after purchasing an additional 45 shares during the last quarter. Traynor Capital Management Inc. boosted its stake in CVS Health by 1.3% during the 2nd quarter. Traynor Capital Management Inc. now owns 3,676 shares of the pharmacy operator’s stock valued at $290,000 after purchasing an additional 48 shares during the last quarter. Sequoia Financial Advisors LLC boosted its stake in CVS Health by 0.8% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 6,406 shares of the pharmacy operator’s stock valued at $515,000 after purchasing an additional 53 shares during the last quarter. Finally, Brookstone Capital Management boosted its stake in CVS Health by 1.8% during the 2nd quarter. Brookstone Capital Management now owns 3,153 shares of the pharmacy operator’s stock valued at $254,000 after purchasing an additional 55 shares during the last quarter. Institutional investors and hedge funds own 81.62% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “CVS Health (CVS) PT Raised to $90.00” was published by Stock Observer and is owned by of Stock Observer. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://www.thestockobserver.com/2018/01/12/cvs-health-cvs-pt-raised-to-90-00.html.
CVS Health Company Profile
CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.